ImpriMed CEO and Co-founder Dr. Sungwon Lim Wins Prestigious “Top Industry Leader” Award from Life Sciences Voice

February 1, 2022

PALO ALTO, CA, UNITED STATES, February 1, 2022 /EINPresswire.com/ -- ImpriMed, Inc., a leading veterinary precision medicine startup, is delighted to announce that its CEO and co-founder, Dr. Sungwon Lim, has been awarded “Top Industry Leader” by the Life Science Voice, where he is listed amongst some of the most influential leaders in the industry, including Presidents, CEOs, and other senior executives’ representative of many prestigious life science companies.

Dr. Lim is a bioengineer and entrepreneur with 20 years of collective experience in academia and biotech companies. He co-founded ImpriMed, a veterinary precision medicine startup that uses artificial intelligence on live cancer cell analytics to predict how a specific patient will respond to cancer therapy drugs before taking them. He has a Ph.D. degree in Bioengineering from Stanford University and a master’s degree in Translational Medicine from the UC Berkeley–UCSF Joint Bioengineering Program.

“I am very honored to be on the list along with the top leaders at many distinguished companies. I would like to thank everyone at ImpriMed who made this happen.”

Dr. Lim was chosen by the Life Sciences Voice community group, which actively tracks industry events and news to assess and select a diverse list of winners who are making a lasting impact in their field of work. This process allows for the discovery and celebration of well-deserving leaders. This award is a highly prestigious and sought-after recognition.

"In 2021, the Life Sciences sector has remained in focus, and many of the leaders have been in the spotlight trying to solve the crisis created by the Covid-19 pandemic," said Jean Coolidge, editor-in-chief of Life Sciences Voice. "It has been an unprecedented year, and many leaders have found themselves in unknown territory dealing with rapid change and accelerated transformation while trying to plan for the new normal. The highly dynamic environment has made the decision-making extremely difficult and onerous."For more information, please visit https://lifescivoice.com/

About Life Sciences Voice
Life Sciences Voice (LSV) is the leading resource for life science executives to get crucial insights, explore the latest innovations, and learn about industry news and trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a wide range of industry issues.

About ImpriMed
ImpriMed provides cutting-edge personalized medicine easily accessible for pets with blood cancers. ImpriMed’s key product, the Personalized Predication Profile, has been used by board-certified veterinary oncologists, helping over 2,500 dogs with lymphoma and leukemia. With ImpriMed services, veterinarians make their treatment decisions quickly and with confidence. This innovative approach to cancer care has been published in two peer-reviewed scientific journal papers, and ImpriMed’s data continues to be presented at major conferences annually. Over 200 veterinary oncologists support ImpriMed services at 130+ specialty hospitals in the US. ImpriMed has raised over $12 million from leading venture capital firms to advance its mission to provide precision medicine for pet cancer care to all. For more information on the company, please visit ImpriMed and direct all media inquiries to press@imprimedicine.com visit www.imprimedicine.com

Contacts
press@imprimedicine.com

Press Releases

ImpriMed Unveils Cancer Treatment Prediction Technology at EHA-SfPM Meeting, Expands AI-Driven Precision Medicine Services from Pets to Humans

Business Wire
Learn More →

ImpriMed Unveils Groundbreaking Cell-Sizing Method for High-Accuracy Feline Lymphoma Characterization in Veterinary Sciences

Business Wire
Learn More →

ImpriMed Launches Innovative AI-Driven Drug Response Predictions (DRP) Service to Guide Tailored Treatments, Meet Rising Demand in Veterinary Oncology

Business Wire
Learn More →

ImpriMed to Showcase Groundbreaking AI Research and Applications at Symposium on Artificial Intelligence in Veterinary Medicine (SAVY)

Business Wire
Learn More →

ImpriMed to Present Innovative Research at 2024 World Veterinary Cancer Congress

Business Wire
Learn More →

ImpriMed Raises $23 Million Series A Round to Expand its Revolutionary AI-Powered Cancer Treatment Technology

Business Wire
Learn More →

ImpriMed Celebrates the Milestone of 4,000 Dog Blood Cancer Patients

Business Insider
Learn More →

ImpriMed Wins Place at the Mayo Clinic Platform_Accelerate Immersive Program

EIN Presswire
Learn More →

40 Under 40 in Cancer Class of 2022 Recognizes Dr. Sungwon Lim, ImpriMed CEO & Co-Founder

EIN Presswire
Learn More →

ImpriMed Presents New Research Findings at The Veterinary Cancer Society (VCS) Mid-Year Conference

EIN Presswire
Learn More →

ImpriMed AI and machine learning is disrupting the veterinary oncology tools available for better treatment outcomes

EIN Presswire
Learn More →

ImpriMed Publishes Exclusive Canine Patients Data Analysis

EIN Presswire
Learn More →

ImpriMed Reports Significant Growth in 2021 with Pre-Series A Funding, New Product Launches, and Team Expansion

EIN Presswire
Learn More →

ImpriMed Launches New Diagnostic Services for Canine Lymphoma

EIN Presswire
Learn More →

ImpriMed Initiates Feline Lymphoma Drug Response Prediction Study

EIN Presswire
Learn More →

ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma

GlobeNewswire
Learn More →

ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market

GlobeNewswire
Learn More →

ImpriMed Launches Advanced Precision Medicine Service for Canine Blood Cancers

PR Underground
Learn More →

ImpriMed Raises $4M for Customized Cancer Treatments for Dogs

GlobeNewswire
Learn More →